GLP-1 receptor agonists reduce kidney failure risk and cardiovascular events Post author: Post published: November 27, 2024 Post category:uncategorized Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes. You Might Also Like Researchers unveil complete neuronal map of fruit fly brain October 4, 2024 Precision medicine enhances prostate cancer treatment with genetic profiling August 20, 2024 Targeted therapy and immunotherapy improve outcomes in rare thyroid cancer October 24, 2024